Eighty Percent Use It, Nobody Can Test It

An estimated 80% of South Africans — approximately 48 million people — use traditional medicines (muthi), often as first-line treatment before or alongside biomedical care. South Africa's 2007 Traditional Health Practitioners Act created a regulatory framework that requires traditional medicines to meet safety and quality standards before commercialization. But the quality assessment methods available — pharmacopoeial standards developed for single-compound pharmaceutical products — are fundamentally mismatched to traditional medicine practice. Traditional preparations typically combine 3–15 plant species, use whole-plant or crude extracts (not purified compounds), and are prepared by individual practitioners using variable sourcing, drying, and extraction methods. Applying single-compound analytical chemistry to multi-component plant preparations does not produce meaningful quality data — it's like evaluating a symphony by measuring the pitch of individual notes without considering the composition.

The safety gap is real: documented cases of heavy metal contamination, microbial contamination, and adulteration with pharmaceutical drugs (notably corticosteroids and anti-inflammatories) in commercial traditional medicine products demonstrate that quality control is needed. But quality control systems designed for the pharmaceutical industry exclude rather than regulate traditional medicine — they set standards that traditional preparations cannot meet by nature, not by deficiency. This leaves the traditional medicine sector effectively unregulated despite the 2007 Act, because the Act's quality provisions are unimplementable with available analytical tools. The regulatory vacuum hurts practitioners (who can't formally validate their products), consumers (who can't distinguish quality from adulterated products), and the health system (which can't integrate traditional and biomedical care without quality assurance).

CSIR Biosciences and South African university pharmacology departments have developed chromatographic fingerprinting methods (HPLC, TLC) that create a "fingerprint" profile of a multi-plant preparation — capturing the overall chemical composition rather than quantifying individual compounds. These fingerprints can detect batch-to-batch variation, identify adulteration, and verify species identity. But fingerprinting alone doesn't address bioactivity: a fingerprint shows what's present, not whether the preparation has the claimed therapeutic effect. Bioassay-guided fractionation (isolating individual active compounds) contradicts the synergistic-whole-preparation model that traditional medicine practitioners assert is the basis of therapeutic action. In vitro bioactivity screens produce results that traditional practitioners consider reductionist and irrelevant to their practice. The methodological gap is both technical (how to measure quality in complex preparations) and epistemological (whose definition of quality applies).

Quality assessment methods designed specifically for multi-component botanical preparations — rather than adapted from single-compound pharmaceutical methods — could bridge the regulatory gap. Metabolomic profiling (comprehensive small-molecule analysis using mass spectrometry) combined with bioactivity-guided fingerprinting could create quality standards that accommodate complexity without requiring single-compound isolation. CSIR researchers have proposed a three-tier quality framework: (1) safety screening (heavy metals, microbial contamination, pharmaceutical adulterants), (2) identity verification (species authentication via DNA barcoding or chemical fingerprint), and (3) consistency assessment (batch-to-batch fingerprint comparison). This framework could be implementable without resolving the deeper epistemological question of how to assess efficacy in complex preparations.

An analytical chemistry team could develop and validate a metabolomic fingerprinting protocol for a specific widely-used traditional medicine preparation, establishing batch-to-batch variability ranges and identifying markers of adulteration or substitution. A regulatory design team could compare quality frameworks for traditional/herbal medicines across jurisdictions (China's TCM Pharmacopoeia, India's Ayurvedic Pharmacopoeia, EU's herbal medicines directive) to identify which approaches could be adapted for South African traditional medicines. A design team could prototype a low-cost, field-deployable quality screening kit that traditional medicine practitioners or retailers could use to test for the most dangerous adulterants (heavy metals, pharmaceutical drugs) without requiring laboratory equipment.